Artificial Intelligence and FDA Oversight: Where We Are Now

Artificial intelligence (AI) is increasingly used in the creation of drugs and devices. As AI is used more broadly in implementing medical care, including a growing number of drug application submissions incorporating AI components, FDA guidance is becoming more crucial. Join us at this half-day conference to hear directly from FDA on its evolving approach to regulating AI as the technology spans the drug product life cycle, device approval, and potential data issues and biases that may arise in using AI modeling for matters such as clinical trials. The conference will feature insights from a diverse group of stakeholders, including FDA and industry representatives, academics, and legal practitioners, providing an opportunity to participate in discussions you won’t want to miss in this rapidly evolving regulatory landscape.